--- title: "Jyong Biotech (MENS) news: going concern, IPO and Nasdaq notice" url: "https://aibio.space/companies/jyong-biotech/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "MENS going concern, IPO and Nasdaq notice news: Jyong Biotech prices $20 million IPO of 2,666,667 shares at $7.50 on Nasdaq. Jyong Biotech Ltd." --- MENS Jyong Biotech Ltd. NASDAQ · Taiwan # Jyong Biotech (MENS) news MENS going concern, IPO and Nasdaq notice news Distress · 2026-04-29 ## [Jyong Biotech files late-filing notice for its 2025 annual report on Form 20-F](https://aibio.space/news/jyong-biotech-files-late-filing-notice-2025-annual-report-form-20/) The company says it needs more time to finalize its audited financial statements and expects to file within 15 calendar days of the due date. ## Latest Jyong Biotech news 1. 2025-06-18 Financings [Jyong Biotech prices $20 million IPO of 2,666,667 shares at $7.50 on Nasdaq](https://aibio.space/news/jyong-biotech-prices-20-million-ipo-2-666-667-shares-7-50-nasdaq/) Jyong Biotech, a Taiwan-based drug developer, priced 2,666,667 shares at $7.50 with Joseph Stone Capital, LLC as sole underwriter. Its lead candidate failed its primary endpoint in a pivotal U.S. trial, its auditor has raised going-concern doubt, and a Chinese court judgment puts about USD 19.4 million at stake. ## Jyong Biotech at a glance - **Ticker**: MENS - **Listing**: NASDAQ - **Country**: Taiwan - **Cash, Dec 31, 2025**: $1.2 million ### Related companies - [TWi Biotechnology](https://aibio.space/companies/twi-biotechnology/) TPEX: 6610 - [Cenra](https://aibio.space/companies/cenra/) TWSE: 3716 - [SYN-TECH Chemical & Pharmaceutical Co.](https://aibio.space/companies/syn-tech-chemical-pharmaceutical/) TPEX: 1777 - [Excelsior Biopharma](https://aibio.space/companies/excelsior-biopharma/) TPEX: 6496 - [Tanvex Biopharma](https://aibio.space/companies/tanvex-biopharma/) TWSE: 6541 - [Formosa Pharmaceuticals](https://aibio.space/companies/formosa-pharmaceuticals/) TWSE: 6838 - [Anya Biopharm](https://aibio.space/companies/anya-biopharm/) TPEX: 7776 - [Timing Pharmaceutical Co.](https://aibio.space/companies/timing-pharmaceutical/) TPEX: 6659 ### Also on NASDAQ - [MiNK Therapeutics](https://aibio.space/companies/mink-therapeutics/) INKT - [BIO-TECHNE](https://aibio.space/companies/bio-techne/) TECH - [Aldeyra Therapeutics](https://aibio.space/companies/aldeyra-therapeutics/) ALDX - [InMed Pharmaceuticals](https://aibio.space/companies/inmed-pharmaceuticals/) INM - [Voyager Therapeutics](https://aibio.space/companies/voyager-therapeutics/) VYGR - [Alpha Cognition](https://aibio.space/companies/alpha-cognition/) ACOG ## Jyong Biotech annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$813,000](https://www.sec.gov/Archives/edgar/data/1954488/000121390026057073/) | [$927,000](https://www.sec.gov/Archives/edgar/data/1954488/000121390026057073/) | | Net income (loss) | [-$4.7 million](https://www.sec.gov/Archives/edgar/data/1954488/000121390026057073/) | [-$3.0 million](https://www.sec.gov/Archives/edgar/data/1954488/000121390026057073/) | | Cash from operations | [-$3.0 million](https://www.sec.gov/Archives/edgar/data/1954488/000121390026057073/) | [-$3.6 million](https://www.sec.gov/Archives/edgar/data/1954488/000121390026057073/) | | Cash and equivalents | [$1.2 million](https://www.sec.gov/Archives/edgar/data/1954488/000121390026057073/) | [$101,000](https://www.sec.gov/Archives/edgar/data/1954488/000121390026057073/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $1.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Jyong Biotech Has Jyong Biotech issued a going-concern warning? Our latest story on this, dated Jun 18, 2025: "Jyong Biotech prices $20 million IPO of 2,666,667 shares at $7.50 on Nasdaq". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/jyong-biotech-prices-20-million-ipo-2-666-667-shares-7-50-nasdaq/). When did Jyong Biotech go public? Our latest story on this, dated Jun 18, 2025: "Jyong Biotech prices $20 million IPO of 2,666,667 shares at $7.50 on Nasdaq". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/jyong-biotech-prices-20-million-ipo-2-666-667-shares-7-50-nasdaq/). Has Jyong Biotech received a Nasdaq deficiency notice? Our latest story on this, dated Apr 29, 2026: "Jyong Biotech files late-filing notice for its 2025 annual report on Form 20-F". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/jyong-biotech-files-late-filing-notice-2025-annual-report-form-20/). What is the ticker symbol of Jyong Biotech? Jyong Biotech Ltd. trades under the ticker MENS on NASDAQ. Where is Jyong Biotech listed? Jyong Biotech Ltd. is listed on NASDAQ. What is the SEC CIK of Jyong Biotech? The SEC Central Index Key (CIK) for Jyong Biotech Ltd. is 1954488. Its filings are on SEC EDGAR. How many shares does Jyong Biotech have outstanding? 76,027,667 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-05-15. Which country or territory is Jyong Biotech listed under? Our directory records Jyong Biotech Ltd. under Taiwan. What does Jyong Biotech do? Our directory classifies Jyong Biotech Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Jyong Biotech? The ISIN recorded for Jyong Biotech Ltd. is KYG831161065. Does aibio.space cover Jyong Biotech? aibio.space lists Jyong Biotech Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Jyong Biotech incorporated? SEC records list its state or country of incorporation as E9. Is Jyong Biotech profitable? Jyong Biotech Ltd. reported a net loss of $4.7 million for the fiscal year ended Dec 31, 2025, and used $3.0 million of cash in operations, per its annual report to the SEC. How much does Jyong Biotech spend on research and development? $813,000 in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Jyong Biotech have? $1.2 million in cash at Dec 31, 2025, per its 20-F. ## Investor discussion: Jyong Biotech Members talk about Jyong Biotech (MENS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Jyong Biotech, newest first. Each line links the filing it comes from. 1. 2026-05-15 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1954488/000121390026057073/ea0287254-20f_jyong.htm) 2. 2026-04-29 Distress Told the SEC a periodic report would be filed late. SEC Form NT 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1954488/000121390026049070/ea0288284-nt20f_jyong.htm) 3. 2025-06-18 Financings Reported a financing. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1954488/000121390025055414/ea0200696-25.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:MENS on TradingView](https://www.tradingview.com/symbols/NASDAQ-MENS/). ## SEC filings and registration - **SEC name**: Jyong Biotech Ltd. - **CIK**: 1954488 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: MENS (Nasdaq) - **State or country of incorporation**: E9 - **Filer category**: Non-accelerated filer
Emerging growth company - **Business address**: 23F-3, NO.95, SEC. 1, XINTAI 5TH RD., NEW TAIPEI CITY - **Phone**: (8862) 27325205 - **Shares outstanding**: 76,027,667 as of 2025-12-31 (20-F filed 2026-05-15) ### Recent filings (8-K and 6-K are the company's own announcements) - [20-F](https://www.sec.gov/Archives/edgar/data/1954488/000121390026057073/ea0287254-20f_jyong.htm) filed 2026-05-15 - [6-K](https://www.sec.gov/Archives/edgar/data/1954488/000121390026013306/ea0275946-6k_jyong.htm) filed 2026-02-06 - [6-K](https://www.sec.gov/Archives/edgar/data/1954488/000121390026002944/ea0271418-6k_jyong.htm) filed 2026-01-09 - [6-K](https://www.sec.gov/Archives/edgar/data/1954488/000121390025055711/ea0246228-6k_jyong.htm) filed 2025-06-20 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001954488), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Jyong Biotech Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MENS, recorded under Taiwan. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Jyong Biotech Ltd. - **Ticker**: MENS - **Listing**: NASDAQ - **Country or territory**: Taiwan - **Business scope**: Pharmaceuticals: Major - **ISIN**: KYG831161065 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-MENS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/jyong-biotech/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Jyong Biotech (MENS) news: going concern, IPO and Nasdaq notice", 2026-10-31, https://aibio.space/companies/jyong-biotech/